Clinical trials: Schizoaffective
Schizophrenia, Schizoaffective Disorder
A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
The purposes of this study are to characterize the pharmacokinetics of paliperidone after single- and multiple-dose administration of paliperidone ER in children and adolescent patients (>= 10 to <= 17 years of age) with…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
- Trial name
- NCT00796081
- Testing
- ER OROS paliperidone, paliperidone ER
- Volunteers
- 25 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorder
Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder
An open-label, multi-center, 6-week, sequential cohort study designed to determine the safety and tolerability of two dose ranges of BL-1020 in hospitalized subjects with chronic schizophrenia or schizo-affective disorder
- Trial name
- NCT00480571
- Testing
- BL-1020, BL 1020 High Dose
- Where
- 2 sites in Israel, Romania
- Volunteers
- 90 people
- Sponsor
- BioLineRx, Ltd.
Schizophrenia, Schizoaffective Disorder
Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS)
The purpose of this study is to prove safety and efficacy of aripiprazole.
- Trial name
- NCT00304655
- Testing
- Aripiprazole
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Schizophrenia, Schizoaffective Disorder
Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone
The primary objective of this study is to evaluate change in weight as a result of switching from quetiapine to ziprasidone, in subjects with schizophrenia or schizoaffective disorder who have failed to achieve a satisfactory…
- Trial name
- NCT00406315
- Testing
- ziprasidone
- Where
- 40 sites in United States, Brazil and 4 more
- Volunteers
- 255 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia, Schizoaffective Disorder
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846)
The primary features of schizophrenia and schizoaffective disorder are positive (inability to think clearly and distinguish reality from fantasy) and negative symptoms (reduction or absence of normal behavior or emotions).
- Trial name
- ACTAMESA (NCT00212771)
- Testing
- asenapine, olanzapine
- Volunteers
- 440 people
- Sponsor
- Organon and Co
Acute Schizophrenia, Schizoaffective Disorder
RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.
- Trial name
- REFRESH (NCT01490086)
- Testing
- RP5063, aripiprazole
- Where
- 15 sites in United States, India and 3 more
- Volunteers
- 234 people
- Sponsor
- Reviva Pharmaceuticals
Bipolar I Disorder, Bipolar II Disorder
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder
This open-label study will utilize treatment with BXCL501 in order to assess the suitability of patient-and lay informant-assessed outcome measures for evaluation of severity of psychomotor agitation episodes in patients with…
- Conditions
- Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT07116694
- Testing
- BXCL501 Sublingual Film
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- BioXcel Therapeutics Inc
Schizophrenia, Diabetes Mellitus
A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to assess and compare how risperidone and olanzapine, two antipsychotic medications, affect the regulation of glucose (sugar) in the body.
- Trial name
- NCT00236379
- Testing
- Olanzapine, Risperidone
- Volunteers
- 59 people
- Sponsor
- Janssen, LP
Negative Symptoms in Schizophrenia, Schizophrenia
NST-SPARK: Preliminary Study of an Augmented Reality (AR) App Delivering Recovery-Oriented Cognitive Therapy for Negative Symptoms in Schizophrenia
This study evaluates the feasibility and acceptability of a prototype for NST-SPARK (version 1.5). This is an augmented reality (AR) mobile phone application that uses Recovery-oriented Cognitive Therapy (CT-R) to target negative…
- Conditions
- Negative Symptoms in Schizophrenia, Schizophrenia, Schizoaffective Disorder
- Trial name
- NST-SPARK-1b (NCT06653829)
- Testing
- SPARK
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- North Shore Therapeutics, Inc.
Schizophrenia, Schizoaffective Disorder
Study on the Safety and Effectiveness of Risperidone Treatment of Acute Psychotic Patients
The purpose of this study was to evaluate the safety of risperidone treatment in acute psychotic patients that require an admission into emergency department.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
- Trial name
- NCT00515489
- Testing
- Risperidone
- Volunteers
- 1,882 people
- Sponsor
- Janssen-Cilag, S.A.
Schizophrenia
A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to document the long-term safety and tolerability of risperidone, formulated as a long-acting injectable, in the treatment of patients with schizophrenia or schizoaffective disorder; in addition, to…
- Trial name
- NCT00210691
- Testing
- Risperidone
- Volunteers
- 273 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorder
Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia
This study is to assess the safety and tolerability of a five-day titration schedule (using twice daily dosing for the first three days) to achieve the highest proposed dose of 40 mg daily. The study duration is two months.
- Trial name
- NCT00139906
- Testing
- Bifeprunox
- Where
- United States
- Sponsor
- Solvay Pharmaceuticals
Schizophrenia, Psychotic Disorders
Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study
This study intends to compare novel antipsychotics ziprasidone and olanzapine, to confirm the findings of an open study -where stable patients receiving olanzapine switched to ziprasidone- which showed maintenance of clinical…
- Trial name
- NCT00145444
- Testing
- olanzapine, ziprasidone
- Where
- 7 sites in Belgium, Netherlands
- Volunteers
- 100 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia, Schizoaffective Disorder
PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective Disorders
The purpose of this study is to evaluate epidemiological characteristics of patients that experience relapse and need an admission in psychiatric acute units across Spain.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00399334
- Testing
- antipsychotic medications
- Volunteers
- 1,607 people
- Sponsor
- Janssen-Cilag, S.A.
Schizophrenia, Schizoaffective Disorder
Broad Effectiveness: Study With Aripiprazole
The purpose of this study is to learn if aripiprazole is effective in the treatment of a large number of persons diagnosed with schizophrenia or schizoaffective disorders
- Trial name
- NCT00036361
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 444 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Smoking Cessation
Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder
Study will determine whether patients with schizophrenia or schizoaffective disorder can be helped to quit smoking safely while using varenicline and receiving smoking cessation counseling.
- Trial name
- NCT00644969
- Testing
- varenicline (CP-526,555)
- Where
- 14 sites in United States, Canada
- Volunteers
- 128 people
- Sponsor
- Pfizer
Schizophrenia, Schizoaffective Disorder
Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder
This study is to assess the tolerability of bifeprunox with the progressive elimination of titration steps to achieve the shortest tolerated titration dosing to a dose of 40 mg/day in either schizophrenia or bipolar disorder…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00139919
- Testing
- Bifeprunox
- Where
- United States
- Sponsor
- Solvay Pharmaceuticals
Schizophrenia, Schizoaffective Disorder
Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)
This study is testing if under the tongue olanzapine for schizophrenia, related psychosis, schizoaffective disorder or bipolar disorder will have less weight gain than olanzapine that is swallowed, in patients who are already…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00303602
- Testing
- Sublingual orally disintegrating olanzapine (SODO), Oral olanzapine
- Where
- 21 sites in United States, Canada and 3 more
- Volunteers
- 149 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Schizoaffective Disorder
Sustainable Early Episode Clinic Study (SEEC)
The purpose of this study is to describe relapse rates among participants receiving services in the SEEC program high intensity resource use.
- Trial name
- SEEC (NCT03571685)
- Testing
- Sustainable Early Episode Clinic Model of Care
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Janssen Scientific Affairs, LLC
Schizophrenia, Schizoaffective Disorder
Schizophrenic Patients Taking Part in Integrated Care Program
Purpose of this non-interventional study (NIS) is to assess the effect of the participation in an integrated care program on treatment outcomes in patients treated with Seroquel for schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreni-form Disorder, Delusional Disorder
- Trial name
- CARE I (NCT00617214)
- Where
- 14 sites in Germany
- Volunteers
- 20 people
- Sponsor
- AstraZeneca